Log in
Enquire now
‌

US Patent 9795604 Methods of treating and preventing graft versus host disease

Patent 9795604 was granted and assigned to Pharmacyclics on October, 2017 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Pharmacyclics
Pharmacyclics
Current Assignee
Pharmacyclics
Pharmacyclics
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
9795604
Patent Inventor Names
Jason A. Dubovsky0
Natarajan Muthusamy0
Amy Jo Johnson0
David Miklos0
John C. Byrd0
Date of Patent
October 24, 2017
Patent Application Number
14523650
Date Filed
October 24, 2014
Patent Citations Received
‌
US Patent 11672803 Use of inhibitors of Brutons tyrosine kinase (Btk)
0
‌
US Patent 12011461 Compositions and methods of hematopoietic stem cell transplants
0
Patent Primary Examiner
‌
My-Chau T. Tran
Patent abstract

Described herein are methods for treating and preventing graft versus host disease using ACK inhibitors. The methods include administering to an individual in need thereof an ACK inhibitor such as ibrutinib for treating and preventing graft versus host disease.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 9795604 Methods of treating and preventing graft versus host disease

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.